Yay!

Not quite an Earthset, but I’ll take it. #AACR

Same for me!

Sold out in Heidelberg and Köln by the time I took notice.

Guilty

Proud of the team including co-first authors Nick Richert and Hana Nuskova, my partner in crime Nikolas Gunkel, and grateful to our collaborators including Slava Ziegler from MPI-Dortmund, and Bozhidar Ivanov and Judy Hirst from @mrc-mbu.bsky.social. (4/4)

This establishes a generalizable design principle for safer proximity-inducing therapeutics. We think that as the field advances, early integration of mitochondrial safety profiling will be essential. (3/4)

Strikingly, we found that some well-known clinically investigated PROTACs are potent complex I inhibitors. In a case study, we demonstrate that the strategic introduction of “kinks” or steric “bumps” into a PROTAC scaffold can abolish complex I inhibition while preserving degrader potency. (2/4)

I'm very excited to share our newest preprint, where we show that long, linear bifunctional molecules like PROTACs can bind within the narrow ubiquinone-binding tunnel of mitochondrial complex I, leading to off-target mitotoxicity.
www.biorxiv.org/cgi/content/...
(1/4)

What are you waiting for? Go work with Elena!

Ad for a postdoc position in centromere biology with colorful chromosomes and centromeres made out of FIMO.

🧪 My lab has an opening for a postdoc position soon! Please share/get in touch!

Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3 - Nature Chemistry In targeted protein degradation, a degrader molecule brings a neosubstrate protein proximal to a hijacked E3 ligase for its ubiquitination. Here, pseudo-natural products derived from (−)-myrtanol—iDeg...

paper alert🚨
Monovalent pseudo-natural products supercharge degradation of IDO1 by its native E3 KLHDC3 - Published by the groups of Herbert Waldmann @waldido.bsky.social , Slava Ziegler and @georgwinter.bsky.social @cemm.oeaw.ac.at in @nature.com Chemistry
www.nature.com/articles/s41...

Now I have a goal. 😉

When is a Monomer not a Monomer? The Top Three Ways Your Favorite Fluorescent Protein Oligomerizes in Cells Many commonly used fluorescent proteins form dimers producing artifacts in a variety of experimental settings. Learn how to avoid these artifacts.

💡 Always a good time to be reminded: "if you fuse your protein of interest to GFP or EGFP to study the protein's behavior ... you are using a tag with a serious drawback."
Same goes for anything that doesn't have 'm' in its name (looking at you, dTomato and StayGold)

Very glad to hear…but not surprised. 😉

Congrats, Alex!

A PhD student from the group is there. Keep an eye out for Nick Richert…he will also give a short talk. Enjoy!!!!

yum

Ouch

Proton Pump Inhibitors Do More Than You Think

I can't believe I missed @dereklowe.bsky.social commenting on our @natchem.nature.com a month ago at "In the Pipeline". I've dreamt for many years that Derek would choose to highlight work coming out of the lab. That feels like a real stamp of approval. Thanks, Derek! www.science.org/content/blog...

You purchased it of course

Our Synthetic Genomics Center "SynGen" is looking for a coordinator, located at @kit.edu Karlsruhe, but coordinating also the U Heidelberg and U Mainz sites.

We are hoping to fill this vacancy ASAP.

For further info, please visit:
www.syn-gen.de/en
www.pse.kit.edu/english/karr...

Please share 🙏

Oh, you figured out what it was. So cool!

What a disappointment

The most recent roadmap problem from our Synthesis Club is up on our shiny new website. This quiz highlights the synthesis of clionastatin B from the group of Jinghuan Gui. www.dkfz.de/en/cancer-dr...

Site-specific activation of the proton pump inhibitor rabeprazole by tetrathiolate zinc centres - Nature Chemistry Proton pump inhibitors (PPIs) are prodrugs that are activated by protonation in the highly acidic environment of the stomach lining. Now, coordination of PPIs to protein-bound zinc ions is revealed as...

Check out our paper on proton pump inhibitor activation (PPI) in cells in Nature Chemistry. Congrats to first author Teresa Marker who started this project in my group and finished it with Tobias Dick (@redoxdkfz.bsky.social). More collabs between our groups to come! doi.org/10.1038/s415...

DKFZ Innovation Management on LinkedIn: #collaboration #innovation #cancerresearch #academicindustrypartnership… Targeting hallmarks of cancer 👏 We are pleased to announce that the project of Dr Nikolas Gunkel of the DKFZ German Cancer Research Center has been awarded a…

Congrats to Niki and the whole team for this new collaboration with Sanofi.
www.linkedin.com/posts/dkfz-i...

Great opportunity to work with an excellent young group leader.

I fully support the name change.

Integrating non-natives. How dare you.